CALGARY, ALBERTA--(Marketwire - Dec. 4, 2007) - Stem Cell Therapeutics Corp. (“SCT”) (TSX VENTURE:SSS) is pleased to announce that the Company has received a No Objection Letter (NOL) from Health Canada for the REGENESIS trial (a Phase II prospective, Randomized, double-blind, placEbo controlled study of NTxTM-265: human chorionic Gonadotropin (hCG) and EpoetiN alfa (EPO) in acute iSchemIc Stroke patients), its Phase IIb clinical trial in acute stroke investigating efficacy and safety endpoints.
